en · de · es · fr · pt
peptide-index.peptides7501.com › News › Identity, Handling, And Regulation — Practical Notes

Identity, Handling, And Regulation — Practical Notes

By Editorial Desk · published 2026-04-17 · last reviewed 2026-05-24 · News

This is a working overview of REV-ERB, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-05-24. Anything still debated is marked as such rather than presented as settled.

Identity, Handling, and Regulation

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Sr9009 at a glance

PropertyValueNotes
AppearanceWhite to off-white solidVisual inspection is not sufficient for identity.
SolubilitySoluble in DMSO and ethanolLow solubility in water.
Typical storage-20 °C, desiccated, darkProtect from repeated temperature changes.
Common analytical methodLC-MS or HPLC-UVReference standard required for comparison.
Common synonymsSR9009; Stenabolic; REV-ERB agonistVendor naming may vary.

Handling Storage and Quality Control

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Related pages on this site

SR9009 Identity and Mechanism

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

Further detail

==== Commander of the Order of the British Empire (CBE) ==== Civil Division Ereman Kasese Ragi. For services to the savings and loan society. Chief Superintendent John Toguata, . For services to the Royal Papua New Guinea Constabulary.

Spironolactone is not generally used in men for the treatment of androgen-dependent dermatological conditions because of its feminizing side effects, but it is effective for such indications in men similarly. As an example, spironolactone has been reported to reduce symptoms of acne in males. An additional example is the usefulness of spironolactone as an antiandrogen in transgender women and nonbinary individuals. Topical spironolactone is effective in the treatment of acne, as well. As a result, topical pharmaceutical formulations containing 2 or 5% spironolactone cream became available in Italy for the treatment of acne and hirsutism in the early 1990s. The products were discontinued in 2006 when the creams were added to the list of doping substances with a decree of the Ministry of Health that year.

Russia launched airstrikes on multiple cities including Kyiv, Dnipro, Kremenchuk, Poltava, Mykolaiv and Uman. At least two missiles hit a nine-story apartment building in Uman killing at least 23 people, and in addition seventeen people were wounded. Two other people were killed in Dnipro. Twenty-one out of the twenty-three missiles were intercepted, as were two "attack drones". Ukrainian Defence Minister Oleksii Reznikov has said that the Ukrainian counteroffensive was "largely ready" to go ahead, subject to weather conditions and approval of commanders.

==== Open Roof Deformity ==== Reduction of a dorsal hump may involve bone (upper vault) and/or cartilage (middle vault). When the bony dorsum (eg, nasal bone) is reduced, there may be a resulting gap in the middle of the nasal bones. This is typically corrected intraoperatively with lateral osteotomies to narrow the nasal bones and remove the gap. However, if the gap is not corrected, then an open roof deformity may result.

Sources: en.wikipedia.org

Supporting material

Although Christianity remains the single most popular religion in the United States, secularism has been growing thanks to Millennials and Generation Z. Among adults born between 2000 and 2006, only about a quarter prayed daily or attended religious service at least once a month. About twenty-nine percent were religiously unaffiliated. Americans who came of age during the 2020s were much more likely to have been raised in secular households. About three quarters of those who grew up in such an environment continued to be irreligious. Among those raised in highly religious households, just under a third still attended religious services regularly or thought of religion as important in their lives. While a slight majority of American teenagers attending public schools wore religious symbols and attire, they were much less likely to pray before lunch or a sport event, invite their peers to join a religious club, and to read religious texts outside of class. Girls were more likely to discuss religion with their friends than boys. Members of Generation Z were more likely to start questioning their parents' religions before the age of 18 than previous cohorts and those who have left typically did not return. Much of the decline of religion in the United States is due to people born after 1990 leaving their families' faiths. Young adults born in the 2000s rarely become Christian after being raised in a non-Christian household.

=== Data queries === Where data entered does not pass validation rules then a data query may be issued to the investigative site where the clinical trial is conducted to request clarification of the entry. Data queries must not be leading (i.e. they must not suggest the correction that should be made). For electronic CRFs only the site staff with appropriate access may modify data entries. For paper CRFs, the clinical data manager applies the data query response to the database and a copy of the data query is retained at the investigative site. When an item or variable has an error or a query raised against it, it is said to have a “discrepancy” or “query”. All EDC systems have a discrepancy management tool or also refer to “edit check” or “validation check” that is programmed using any known programming language (e.g. SAS, PL/SQL, C#, SQL, Python, etc). So what is a ‘query’? A query is an error generated when a validation check detects a problem with the data. Validation checks are run automatically whenever a page is saved “submitted” and can identify problems with a single variable, between two or more variables on the same eCRF page, or between variables on different pages. A variable can have multiple validation checks associated with it. Errors can be resolved in several ways:

==== FASTER ==== The FASTER algorithm uses a combination of deterministic and stochastic criteria to optimize amino acid sequences. FASTER first uses DEE to eliminate rotamers that are not part of the optimal solution. Then, a series of iterative steps optimize the rotamer assignment.

Sources: en.wikipedia.org

Notes from published material

=== Generic names === Naltrexone is the generic name of the drug and its INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, BANTooltip British Approved Name, DCFTooltip Dénomination Commune Française, and DCITTooltip Denominazione Comune Italiana, while naltrexone hydrochloride is its USPTooltip United States Pharmacopeia and BANMTooltip British Approved Name.

The dynamics of an epidemic, for example, the flu, are often much faster than the dynamics of birth and death, therefore, birth and death are often omitted in simple compartmental models. The SIR system without so-called vital dynamics (birth and death, sometimes called demography) described above can be expressed by the following system of ordinary differential equations:

After starting a collaboration on heart applications with Robert Weiss at Johns Hopkins, Paul returned to Johns Hopkins University in 1994, as Professor and Director of the MR Research Division. He worked on the application of MRS to measure cardiac energy metabolism in the healthy and ischemic human heart, finding that creatine kinase energy supply was compromised in heart failure, that it declined in relation to cardiac mechanical work and that it was an independent predictor of cardiac events and death. More recent work showed that a neural network based on cardiac CK metabolic parameters alone could differentiate a number of different types of cardiac disease and severity with potentially clinically useful accuracy. Paul has also worked on developing interventional MRI technology, specifically, tiny MRI detector coils that can be built into catheters to perform high resolution imaging of vessel wall and surrounding tissues; accelerated to perform real-time high resolution 'MRI endoscopy'; and potentially combined with extra-vascular therapy delivery. The earlier work led to the founding of the SurgiVision Inc start-up noted at top, and later, the development of MRI-safe implantable lead technology (licensed and sold as Avista™ by Boston Scientific Inc).

=== Jiffy === In computing, the jiffy is the duration of one tick of the system timer interrupt. Typically, this time is 0.01 seconds, though in some earlier systems (such as the Commodore 8-bit machines) the jiffy was defined as 1⁄60 of a second, roughly equal to the vertical refresh period (i.e. the field rate) on NTSC video hardware (and the period of AC electric power in North America).

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 usually analyzed?

Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.

What storage conditions are typical?

The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.

Is SR9009 legal to purchase?

Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

Network